TY - JOUR
T1 - B-cell activity markers are associated with different disease activity domains in primary Sjögren's syndrome
AU - James, Katherine
AU - Chipeta, Chimwemwe
AU - Parker, Antony
AU - Harding, Stephen
AU - Cockell, Simon J.
AU - Gillespie, Colin S.
AU - Hallinan, Jennifer
AU - Barone, Francesca
AU - Bowman, Simon J.
AU - Ng, Wan Fai
AU - Fisher, Benjamin A.
AU - Hall, Frances
AU - Bacabac, Elalaine C.
AU - Frankland, Helen
AU - Moots, Robert
AU - Chadravarty, Kuntal
AU - Lamabadusuriya, Shamin
AU - Bombardieri, Michele
AU - Pitzalis, Constantino
AU - Sutcliffe, Nurhan
AU - Breston, Celia
AU - Gendi, Nagui
AU - Culfear, Karen
AU - Riddell, Claire
AU - Hamburger, John
AU - Richards, Andrea
AU - Rauz, Saaeha
AU - Brailsford, Sue
AU - Dasgin, Joanne
AU - Logan, Joanne
AU - Mulherin, Diarmuid
AU - Andrews, Jacqueline
AU - Emery, Paul
AU - McManus, Alison
AU - Pease, Colin
AU - Pickles, David
AU - Booth, Alison
AU - Regan, Marian
AU - King, Jon
AU - Holt, Amanda
AU - Dimitroulas, Theodoros
AU - Kadiki, Lucy
AU - Kaur, Daljit
AU - Kitas, George
AU - Khan, Abdul
AU - Cosier, Tracey
AU - Panthakalam,
AU - Mintrim, Kelly
AU - Lloyd, Mark
AU - Moore, Lisa
AU - UK Primary Sjögren's Syndrome Registry
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Objectives. B-cell activating factor (BAFF), β-2 microglobulin (β2M) and serum free light chains (FLCs) are elevated in primary SS (pSS) and associated with disease activity. We aimed to investigate their association with the individual disease activity domains of the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) in a large well-characterized pSS cohort. Methods. Sera from pSS patients enrolled in the UK Primary Sjögren's Syndrome Registry (UKPSSR) (n = 553) and healthy controls (n = 286) were analysed for FLC (κ and λ), BAFF and β2M. Pearson correlation coefficients were calculated for patient clinical characteristics, including salivary flow, Schirmer's test, EULAR Sjögren's Syndrome Patient Reported Index and serum IgG levels. Poisson regression was performed to identify independent predictors of total ESSDAI and ClinESSDAI (validated ESSDAI minus the biological domain) scores and their domains. Results. Levels of BAFF, β2M and FLCs were higher in pSS patients compared to controls. All three biomarkers associated significantly with the ESSDAI and the ClinESSDAI. BAFF associated with the peripheral nervous system domain of the ESSDAI, whereas β2M and FLCs associated with the cutaneous, biological and renal domains. Multivariate analysis showed BAFF, β2M and their interaction to be independent predictors of ESSDAI/ClinESSDAI. FLCs were also shown to associate with the ESSDAI/ ClinESSDAI but not independent of serum IgG. Conclusion. All biomarkers were associated with total ESSDAI scores but with differing domain associations. These findings should encourage further investigation of these biomarkers in longitudinal studies and against other disease activity measures.
AB - Objectives. B-cell activating factor (BAFF), β-2 microglobulin (β2M) and serum free light chains (FLCs) are elevated in primary SS (pSS) and associated with disease activity. We aimed to investigate their association with the individual disease activity domains of the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) in a large well-characterized pSS cohort. Methods. Sera from pSS patients enrolled in the UK Primary Sjögren's Syndrome Registry (UKPSSR) (n = 553) and healthy controls (n = 286) were analysed for FLC (κ and λ), BAFF and β2M. Pearson correlation coefficients were calculated for patient clinical characteristics, including salivary flow, Schirmer's test, EULAR Sjögren's Syndrome Patient Reported Index and serum IgG levels. Poisson regression was performed to identify independent predictors of total ESSDAI and ClinESSDAI (validated ESSDAI minus the biological domain) scores and their domains. Results. Levels of BAFF, β2M and FLCs were higher in pSS patients compared to controls. All three biomarkers associated significantly with the ESSDAI and the ClinESSDAI. BAFF associated with the peripheral nervous system domain of the ESSDAI, whereas β2M and FLCs associated with the cutaneous, biological and renal domains. Multivariate analysis showed BAFF, β2M and their interaction to be independent predictors of ESSDAI/ClinESSDAI. FLCs were also shown to associate with the ESSDAI/ ClinESSDAI but not independent of serum IgG. Conclusion. All biomarkers were associated with total ESSDAI scores but with differing domain associations. These findings should encourage further investigation of these biomarkers in longitudinal studies and against other disease activity measures.
KW - B cells
KW - B-cell activating factor
KW - Biomarker
KW - Disease activity
KW - Free light chains
KW - Sjögren's syndrome
KW - β-2 microglobulin
UR - http://www.scopus.com/inward/record.url?scp=85051473603&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/key063
DO - 10.1093/rheumatology/key063
M3 - Article
AN - SCOPUS:85051473603
SN - 1462-0324
VL - 57
SP - 1222
EP - 1227
JO - Rheumatology (United Kingdom)
JF - Rheumatology (United Kingdom)
IS - 7
ER -